Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Pharma Mar

Gilead Sciences

Gilead gets EU nod for TAF-based triple therapy for HIV

Once-daily, single-tablet Odefsey reduces risks of side effects such as renal and bone toxicity

National Institute for Health and Care Excellence NICE logo

NICE backs five new drugs after discounts agreed

Includes Novartis’ previously rejected lung cancer and melanoma therapies Zykadia and Mekinist

- PMLiVE

Amgen promotes Esteban Santos

He succeeds Madhavan Balachandran as executive vice president of operations

- PMLiVE

SMC rejects Amgen’s Repatha over lack of outcomes data

But gives GlaxoSmithKline’s asthma drug Nucala the green light

- PMLiVE

SMC approves Amgen orphan drug for use in NHS Scotland

Also accepts AbbVie's former orphan drug Duodopa, but rejects Sanofi's Jevtana

Gilead Sciences

Gilead, Merck get CHMP backing for new hep C combinations

Approval of Epclusa and Zepatier will see the pan-genotypic drugs compete for market share

dengue fever mosquito

Malaria vaccine is first to provide ‘sustained protection’

Latest trial shows immunological response lasts for at least a year

National Institute for Health and Care Excellence NICE logo

NICE persuaded to back Praluent as well as Repatha

Comes after Sanofi follows Amgen in discounting the price of its drug

Allergan logo

Allergan eyes early 2017 European launch for Enzepi

CHMP backs the enzyme replacement therapy's approval

AstraZeneca AZ

CHMP backs AZ’s ‘superbug’ antibiotic product

Zavicefta recommended for European approval

- PMLiVE

Gilead bags EU approval for next-generation HIV drug

Descovy expected to replace Truvada as the firm’s lead antiviral blockbuster

- PMLiVE

Does safety sell medicines?

Is pharmacovigilance unnecessary policing or a strategic asset for pharma companies?

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links